CTU: A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors

  • Sabanathan, Dhanusha (Primary Chief Investigator)
  • Quinlan, Gabriel (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Martin, Lewis (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Garcia, Michelle (Clinical Trial Unit Staff)
  • Armstrong, Emilia (Clinical Trial Unit Staff)
  • McHugh, Tracey (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleIKS014-01
StatusFinished
Effective start/end date1/10/24 → 7/07/25